New research shows that a protein called Muc4 may be the essential ingredient that allows breast cancer to spread to other organs and resist therapeutic treatment. New research from UC Davis Cancer ...

We studied MUC4 expression in human HNSCC tissues and investigated its functional role in HNSCC cell lines. We observed significant upregulation of MUC4 in HNSCC tissues compared with normal tissues.

Homologous recombination deficiency (HRD) scoring in pancreatic ductal adenocarcinoma (PDAC) and response to chemotherapy. This is an ASCO Meeting Abstract from the 2020 Gastrointestinal Cancers ...

The tracheobronchial mucin MUC4 is a ligand for the ErbB2 tyrosine kinase, and influences expression of p27, a cyclin-dependent kinase inhibitor that regulates the G1 and S phases of the cell cycle.

Data suggests in triple negative breast cancer that MUC4 predicts survival and resistance to immunotherapy and that INB03 reverses resistance by decreasing immunosuppression in the TME Boca Raton, ...

UC Davis Cancer Center scientists say the Muc4 protein may be the key to breast cancer’s spread to other organs and resistance to therapeutic treatment. The study, published in the April 1 issue of ...

Boca Raton, April 11, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate ...

(SACRAMENTO, Calif.) — New research from UC Davis Cancer Center shows that a protein called Muc4 may be the essential ingredient that allows breast cancer to spread to other organs and resist ...

INB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast cancer and increases the ...

The EGFR family consists of four different members: EGFR; human epidermal growth factor receptor (HER) 2; HER3; and HER4. Upon ligand binding, these receptors can homodimerize or heterodimerize with ...

Baseline demographics of patients with neuroendocrine tumors presenting to seven National Comprehensive Cancer Network (NCCN) institutions: Development of a multi-institutional outcomes database.